Investors should consider buying Johnson & Johnson (JNJ) stock for steady growth and reasonable valuation.

From Zacks Investment Research: 2025-03-04 18:44:11

Markets are selling off as investors react to tariff implications and geopolitical tensions, but Johnson & Johnson (JNJ) stands out with a stock hitting new highs and up 16% year to date. The pharmaceutical giant offers a wide range of medical solutions, with $88.82 billion in revenue projected to grow by 3% in 2026. Annual earnings are expected to rise by 6% this year to $10.58 per share, with a forward earnings multiple of 15.8X. JNJ stock is currently a Zacks Rank #3 (Hold), offering a potential hedge against market volatility with steady growth and reasonable valuation.



Read more at Zacks Investment Research: Buy Johnson & Johnson (JNJ) Stock for Higher Highs? – March 4, 2025